JP2005527512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527512A5 JP2005527512A5 JP2003574126A JP2003574126A JP2005527512A5 JP 2005527512 A5 JP2005527512 A5 JP 2005527512A5 JP 2003574126 A JP2003574126 A JP 2003574126A JP 2003574126 A JP2003574126 A JP 2003574126A JP 2005527512 A5 JP2005527512 A5 JP 2005527512A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- bryostatin
- medicament according
- agent
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 48
- 239000003795 chemical substances by application Substances 0.000 claims 23
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical class C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 13
- 150000002596 lactones Chemical class 0.000 claims 13
- 229930192344 Neristatin Chemical class 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 9
- 229960005539 bryostatin 1 Drugs 0.000 claims 8
- 230000003931 cognitive performance Effects 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 7
- 239000012190 activator Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 6
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 230000000324 neuroprotective effect Effects 0.000 claims 4
- 208000037259 Amyloid Plaque Diseases 0.000 claims 3
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 229960005520 bryostatin Drugs 0.000 claims 3
- AVJAOOKIOFJJOC-VXOITNNESA-N bryostatin 18 Chemical compound C([C@H]1O[C@@](C([C@@H](OC(=O)C(C)(C)C)C1)(C)C)(O)C[C@@H]1C/C(C[C@H](/C=C/C2(C)C)O1)=C/C(=O)OC)[C@@H](O)CC(=O)O[C@@H]([C@@H](C)O)C[C@@H]1C\C(=C\C(=O)OC)C[C@@]2(O)O1 AVJAOOKIOFJJOC-VXOITNNESA-N 0.000 claims 3
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000007505 plaque formation Effects 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 230000009134 cell regulation Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000000412 Avitaminosis Diseases 0.000 claims 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021135 Hypovitaminosis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Pseudoisatin Natural products C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 230000000142 dyskinetic effect Effects 0.000 claims 1
- 238000002635 electroconvulsive therapy Methods 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 208000030401 vitamin deficiency disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36208002P | 2002-03-07 | 2002-03-07 | |
| US10/167,491 US6825229B2 (en) | 2002-03-07 | 2002-06-13 | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| PCT/US2003/007101 WO2003075850A2 (en) | 2002-03-07 | 2003-03-07 | Methods for alzheimer's disease treatment and cognitive enhancement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527512A JP2005527512A (ja) | 2005-09-15 |
| JP2005527512A5 true JP2005527512A5 (enExample) | 2006-06-15 |
Family
ID=27807411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574126A Withdrawn JP2005527512A (ja) | 2002-03-07 | 2003-03-07 | アルツハイマー病の治療および認知増強のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US6825229B2 (enExample) |
| EP (2) | EP1490050B1 (enExample) |
| JP (1) | JP2005527512A (enExample) |
| AU (1) | AU2003220096A1 (enExample) |
| CA (1) | CA2477973A1 (enExample) |
| ES (1) | ES2639578T3 (enExample) |
| WO (1) | WO2003075850A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20070037871A1 (en) * | 2002-07-02 | 2007-02-15 | Blanchette Rockefeller Neurosciences Instiute | Pkc activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds |
| US6825229B2 (en) * | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| EP1551387A4 (en) * | 2002-07-02 | 2007-10-10 | Brni Neurosciences Inst | PKC ACTIVATION AS A MEANS TO GAIN THE SAPP-A SECRETION AND IMPROVE THE COGNITION USING BRYOSTATIN-TYPE COMPOUNDS |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| WO2006094673A2 (en) * | 2005-03-08 | 2006-09-14 | Ludwig-Maximilians-Universität München | Synergistic mixtures of c6- to c12-alkanedi0ls and tropolone (derivatives) |
| EP1915145A1 (en) * | 2005-07-29 | 2008-04-30 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| WO2007044094A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| EP2762136A1 (en) * | 2006-07-28 | 2014-08-06 | Blanchette Rockefeller Neurosciences, Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| US20170319541A9 (en) * | 2006-07-28 | 2017-11-09 | Blanchette Rockefeller Neuroscience Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| DK2048145T3 (da) * | 2006-08-04 | 2011-04-04 | Toyama Chemical Co Ltd | Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf |
| EP3332797A3 (en) * | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury |
| WO2008112585A2 (en) * | 2007-03-09 | 2008-09-18 | Qualcomm Incorporated | Quadrature modulation rotating training sequence |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| WO2009099563A2 (en) * | 2008-02-05 | 2009-08-13 | Blanchette Rockefeller Neurosciences Institute | Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
| EP2283023A2 (en) | 2008-04-16 | 2011-02-16 | University of Utah Research Foundation | Bryostatin analogues and methods of making and using thereof |
| JP2011529344A (ja) | 2008-07-28 | 2011-12-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | アルツハイマー病の刺激誘発ゲノムプロフィールマーカー |
| US20110023152A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of cognition related genes in animals |
| CA2790680C (en) * | 2010-02-22 | 2019-02-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels |
| CA2804789A1 (en) | 2010-07-08 | 2012-01-12 | Daniel L. Alkon | Pkc activators and anticoagulant in regimen for treating stroke |
| US9597312B2 (en) * | 2010-08-19 | 2017-03-21 | Cognitive Research Enterprises, Inc. | Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators |
| EP2776018B1 (en) | 2011-11-13 | 2021-08-25 | Cognitive Research Enterprises, Inc. | Pkc activators and combinations thereof |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| EP2925314B1 (en) | 2012-11-28 | 2020-04-01 | Aphios Corporation | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
| WO2014145316A1 (en) | 2013-03-15 | 2014-09-18 | Alkon Daniel L | Methods for identifying neuroprotective pkc activators |
| WO2016183252A1 (en) | 2015-05-11 | 2016-11-17 | Alkon, Daniel, L. | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele |
| US20180256537A1 (en) | 2015-09-23 | 2018-09-13 | Tapan K. Khan | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| US20180311209A1 (en) | 2015-10-08 | 2018-11-01 | Cognitive Research Enterprises, Inc. | Dosing regimens of pkc activators |
| MX2018013324A (es) * | 2016-05-04 | 2019-08-01 | Neurotrope Bioscience Inc | Métodos y composiciones para el tratamiento del síndrome de rett. |
| EP3964210A1 (en) * | 2018-05-18 | 2022-03-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US12297244B2 (en) | 2019-06-05 | 2025-05-13 | Rensselaer Polytechnic Institute | Systems and methods for inhibiting γ-secretase production of amyloid-β peptides |
| WO2022132856A1 (en) * | 2020-12-16 | 2022-06-23 | Synaptogenix, Inc. | Treatment of amyotrophic lateral sclerosis using pkc activators |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| FI840260L (fi) | 1983-01-27 | 1984-07-28 | Ciba Geigy Ag | Pyrrolidinonderivat och foerfarande foer deras framstaellning. |
| US4611066A (en) | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5955501A (en) | 1986-06-11 | 1999-09-21 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators O |
| US5891906A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
| US5962498A (en) | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
| US6043270A (en) * | 1986-06-11 | 2000-03-28 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators V |
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US4833257A (en) | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| JP2973322B2 (ja) | 1988-01-13 | 1999-11-08 | アリゾナ ボード オブ リーゼンツ | 免疫調整剤 |
| US4833139A (en) | 1988-01-25 | 1989-05-23 | Hoechst-Roussel Pharmaceuticals, Inc. | Enhancing cholinergic activity with 5-substituted 1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinones and related compounds |
| DE3827974A1 (de) | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| US4994472A (en) | 1989-08-02 | 1991-02-19 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-(pyridinylamino)-2-pyrrolidinones as pain relievers |
| EP0502060A4 (en) | 1989-11-13 | 1993-05-05 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| JP2578001B2 (ja) * | 1989-12-11 | 1997-02-05 | 明治製菓株式会社 | 抗痴呆薬 |
| EP0562025B1 (en) | 1990-12-06 | 2001-02-07 | Affymetrix, Inc. (a Delaware Corporation) | Compounds and their use in a binary synthesis strategy |
| US5072004A (en) | 1990-12-31 | 1991-12-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthetic conversion of bryostatin 2 into bryostatin 1 |
| US5981165A (en) | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
| US5196447A (en) | 1991-08-08 | 1993-03-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University | Neristatin 1 |
| WO1993009668A1 (en) | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
| US5359115A (en) | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| PT665897E (pt) | 1992-10-01 | 2003-11-28 | Trustees Of Columbia U In The | Bibliotecas quimicas combinatorias complexas codificadas com etiquetas |
| JPH06279311A (ja) * | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US5580748A (en) | 1993-05-03 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic tests for alzheimers disease |
| US5393897A (en) | 1993-07-02 | 1995-02-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of spongistatins 5,7,8 and 9 |
| US5362899A (en) | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| CA2173131A1 (en) | 1993-09-30 | 1995-04-06 | Koichi Shudo | Benzolactam derivatives |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5430053A (en) * | 1994-04-19 | 1995-07-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of dictyostatin 1 |
| US5625232A (en) | 1994-07-15 | 1997-04-29 | Texas Instruments Incorporated | Reliability of metal leads in high speed LSI semiconductors using dummy vias |
| EP0854874B1 (en) | 1994-11-10 | 2003-05-02 | Pfizer Inc. | Macrocyclic lactone compounds and their production process |
| GB9509572D0 (en) * | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
| WO1997043268A1 (en) | 1996-05-10 | 1997-11-20 | Georgetown University | 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and their use as protein kinase c (=pkc) modulators |
| GB9620390D0 (en) * | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB9701675D0 (en) | 1997-01-28 | 1997-03-19 | Bridgeman Keith | Composition for the treatment of parkinson's disease |
| US5962504A (en) | 1997-09-08 | 1999-10-05 | Georgetown University | Substituted 2-pyrrolidinone activators of PKC |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| DE19943198A1 (de) | 1999-09-09 | 2001-03-15 | Meyer Lucas Gmbh & Co | Therapeutikum zur Behebung zentralnervöser Funktionsstörungen |
| AU784589B2 (en) | 1999-11-30 | 2006-05-04 | Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| JP2001240581A (ja) * | 2000-02-29 | 2001-09-04 | Senju Pharmaceut Co Ltd | アミノベンズアミド誘導体およびその用途 |
| AU2001243635A1 (en) | 2000-03-14 | 2001-09-24 | Brown University Research Foundation | Methods and compositions for regulating memory consolidation |
| WO2001083449A2 (en) * | 2000-04-28 | 2001-11-08 | Georgetown University | Rigid pyrrolidone modulators of pkc |
| AUPQ801700A0 (en) | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| US20030050302A1 (en) * | 2000-08-31 | 2003-03-13 | Neurologic, Inc. | Treatment of conditions associated with amyloid processing using PKC activators |
| DE60028376T2 (de) | 2000-10-09 | 2007-06-06 | Rath, Matthias, Dr. | Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses |
| US6689385B2 (en) | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| AUPR215700A0 (en) | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| PL364081A1 (en) | 2001-03-01 | 2004-12-13 | Pfizer Products Inc. | Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| WO2002083877A1 (en) | 2001-04-11 | 2002-10-24 | Stem Cell Therapeutics Inc. | Production of tyrosine hydroxylase positive neurons |
| WO2002086106A1 (en) | 2001-04-23 | 2002-10-31 | Nsgene A/S | Method and culture medium for producing neural cells expressing tyrosine hydroxylase |
| ATE411019T1 (de) | 2001-05-02 | 2008-10-15 | Brni Neurosciences Inst | Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung |
| CA2401452A1 (en) | 2001-09-04 | 2003-03-04 | Uri Saragovi | Combination of antioxidant substances for the treatment of alzheimer's disease |
| JP4568464B2 (ja) | 2001-11-07 | 2010-10-27 | 雪印乳業株式会社 | 記憶障害予防治療剤 |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US6821979B2 (en) | 2002-03-07 | 2004-11-23 | Blanchette Rockefeller Neurosciences Institute | Synergistic enhancement of cognitive ability |
| EP1551387A4 (en) * | 2002-07-02 | 2007-10-10 | Brni Neurosciences Inst | PKC ACTIVATION AS A MEANS TO GAIN THE SAPP-A SECRETION AND IMPROVE THE COGNITION USING BRYOSTATIN-TYPE COMPOUNDS |
| US20040229292A1 (en) | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
| US7803400B2 (en) | 2002-12-03 | 2010-09-28 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| NZ546226A (en) | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| EP1915145A1 (en) | 2005-07-29 | 2008-04-30 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| EP2762136A1 (en) | 2006-07-28 | 2014-08-06 | Blanchette Rockefeller Neurosciences, Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| EP3332797A3 (en) | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury |
| JP5987867B2 (ja) | 2014-07-10 | 2016-09-07 | コニカミノルタ株式会社 | シート搬送装置および画像形成システム |
-
2002
- 2002-06-13 US US10/167,491 patent/US6825229B2/en not_active Expired - Lifetime
-
2003
- 2003-03-07 AU AU2003220096A patent/AU2003220096A1/en not_active Abandoned
- 2003-03-07 EP EP03716386.2A patent/EP1490050B1/en not_active Expired - Lifetime
- 2003-03-07 ES ES10000734.3T patent/ES2639578T3/es not_active Expired - Lifetime
- 2003-03-07 WO PCT/US2003/007101 patent/WO2003075850A2/en not_active Ceased
- 2003-03-07 CA CA002477973A patent/CA2477973A1/en not_active Abandoned
- 2003-03-07 EP EP10000734.3A patent/EP2172246B1/en not_active Expired - Lifetime
- 2003-03-07 JP JP2003574126A patent/JP2005527512A/ja not_active Withdrawn
-
2004
- 2004-09-03 US US10/933,536 patent/US20050037984A1/en not_active Abandoned
-
2013
- 2013-03-27 US US13/851,161 patent/US9539235B2/en not_active Expired - Fee Related
-
2015
- 2015-11-02 US US14/929,731 patent/US9446020B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527512A5 (enExample) | ||
| Manconi et al. | Sleep architecture in insomniacs with severe benzodiazepine abuse | |
| Sulekha et al. | Evaluation of sleep architecture in practitioners of Sudarshan Kriya yoga and Vipassana meditation | |
| HK1048073A1 (en) | Use of xenon for treating neurointoxications | |
| HRP20110570T1 (hr) | Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora | |
| EP3332797A3 (en) | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury | |
| JP2020186274A5 (enExample) | ||
| IL315023A (en) | Neuroactive steroids for treatment of cns-related disorders | |
| BRPI0407832A (pt) | inibidor de pten ou abridor dos canais maxi-k | |
| WO2010018996A3 (ko) | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 | |
| PT1689404E (pt) | Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro | |
| RU2418587C1 (ru) | Способ лечения злокачественных опухолей головного мозга | |
| BRPI0511941A (pt) | uso de (s, s)-reboxetina ou reboxetina racêmica | |
| KR20110011748A (ko) | 각성을 향상시키는 방법 | |
| Cirignotta et al. | Partial motor epilepsy with “negative myoclonus” | |
| Lauterbach et al. | Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications | |
| RU2253486C2 (ru) | Способ химиотерапии опухолей центральной нервной системы | |
| Millichap et al. | Controlled evaluation of primidone and diphenylhydantoin sodium: comparative anticonvulsant efficacy and toxicity in children | |
| RU2577950C1 (ru) | Способ стимуляции заживления дермальных ожогов | |
| WO2021231582A1 (en) | Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia | |
| Sadigh | The treatment of recalcitrant post-traumatic nightmares with autogenic training and autogenic abreaction: A case study | |
| EA200801278A1 (ru) | Способ коррекции функциональных расстройств организма человека | |
| KR200370966Y1 (ko) | 가발 | |
| CN101732132A (zh) | 耳脑医疗保健仪 | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |